coronavirus
cov
traffic
frequent
speci
result
novel
diseas
outbreak
recent
exemplifi
newli
emerg
herein
show
ribonucleosid
analog
hydroxycytidin
nhc
broad
spectrum
antivir
activ
sarscov
merscov
sarscov
genet
divers
orthocoronavirina
coronaviru
cov
famili
circul
mani
avian
mammalian
speci
phylogenet
cov
divid
genera
alpha
group
beta
group
gamma
group
delta
group
three
determin
nhc
would
increas
mutat
frequenc
merscov
infect
human
primari
human
airway
epitheli
cell
hae
use
merscov
infect
hae
treat
either
vehicl
dose
rang
nhc
rdv
show
drug
reduc
viru
titer
dosedepend
manner
fig
employ
sensit
highfidel
deep
sequenc
approach
primer
id
ng
use
barcod
degener
primer
illumina
index
librari
determin
accur
mutat
rate
antivir
treatment
viral
rna
product
use
approach
analyz
region
viral
genom
rna
nonstructur
protein
error
rate
base
vehicl
rdv
treat
cultur
low
rdv
report
act
via
chain
termin
nascent
viral
rna
thu
low
error
rate
rdvtreat
cultur
line
propos
moa
contrast
error
rate
significantli
increas
nhctreat
cov
rna
dosedepend
manner
fig
magnitud
error
rate
nhctreat
cultur
correl
viru
titer
reduct
respect
error
rate
viru
titer
pfuml
vehicl
treatment
pfuml
nhc
pfuml
nhc
thu
nhc
increas
error
rate
result
decreas
viru
titer
nhc
increas
error
rate
result
decreas
viru
titer
examin
mutat
spectra
induc
nhc
incorpor
viral
rna
substitut
either
cytosin
c
uridin
u
mutagen
antivir
may
incorpor
nascent
neg
posit
sens
rna
genom
replic
fig
adeninetoguanin
atog
uraciltocytosin
utoc
transit
enrich
merscov
genom
rna
nhc
depend
manner
fig
collect
data
use
highfidel
sequenc
analysi
demonstr
specif
enrich
g
c
u
transit
cov
rna
nhc
treatment
primari
hae
cell
cultur
therapeut
reduc
sarscov
replic
pathogenesi
ester
design
improv
vivo
pharmacokinet
oral
bioavail
human
nonhuman
primat
importantli
plasma
profil
nhc
similar
mice
follow
oral
deliveri
first
perform
prophylact
dose
escal
studi
mice
oral
administ
vehicl
peg
cremophor
water
mgkg
prior
intranas
infect
pfu
mouseadapt
sarscov
everi
thereaft
begin
end
studi
bodi
weight
loss
compar
vehicl
treatment
significantli
diminish
prevent
prophylaxi
p
supplement
figur
lung
hemorrhag
also
significantli
reduc
treatment
supplement
figur
interestingli
dosedepend
reduct
sarscov
lung
titer
median
titer
pfuml
pfuml
pfuml
vehicl
pfuml
signific
differ
among
vehicl
mgkg
p
p
group
thu
prophylact
oral
administ
robustli
antivir
abl
prevent
sarscov
replic
diseas
sinc
group
significantli
diminish
weight
loss
hemorrhag
reduc
lung
titer
near
undetect
level
test
dose
therapeut
treatment
condit
determin
could
improv
outcom
ongo
cov
infect
control
initi
oral
vehicl
prior
infect
pfu
therapeut
condit
initi
treatment
infect
initi
treatment
dose
group
perform
everi
durat
studi
prophylact
treatment
initi
prior
infect
therapeut
treatment
initi
infect
significantli
prevent
bodi
weight
loss
follow
sarscov
infect
thereaft
p
p
fig
treatment
initi
also
significantli
reduc
bodi
weight
loss
p
although
degre
earlier
treatment
initi
group
initi
bodi
weight
loss
differ
vehicl
p
initi
infect
mirror
bodi
weight
loss
phenotyp
fig
interestingli
treat
mice
significantli
reduc
viral
load
lung
even
group
fig
experienc
least
protect
bodi
weight
loss
lung
hemorrhag
also
measur
pulmonari
function
via
whole
bodi
plethysmographi
wpb
figur
show
wbp
penh
metric
surrog
marker
bronchoconstrict
pulmonari
obstruct
significantli
improv
throughout
cours
studi
treatment
initi
infect
although
group
show
sporad
improv
well
fig
lastli
blindli
evalu
hematoxylin
eosin
stain
lung
tissu
section
histolog
featur
ali
use
two
differ
complementari
score
tool
show
treatment
initi
significantli
reduc
ali
evalu
therapeut
efficaci
follow
promis
result
prophylact
studi
similar
sarscov
studi
treatment
administ
intranas
mouseadapt
merscov
infect
pfu
prevent
bodi
weight
loss
fig
p
lung
hemorrhag
fig
p
treatment
initi
offer
similar
protect
unlik
bodi
weight
loss
lung
hemorrhag
data
vari
treatment
initi
time
viru
lung
titer
significantli
reduc
limit
detect
treatment
group
fig
p
interestingli
viral
genom
rna
quantifi
pair
sampl
lung
tissu
significantli
reduc
level
viral
rna
p
initi
timedepend
manner
group
except
fig
studi
molecular
mechan
associ
drug
perform
vivo
investig
correl
infecti
viru
product
mediat
mutagenesi
merscov
rna
therapeut
treatment
condit
use
primer
id
ng
measur
mutat
rate
viral
genom
rna
ie
indic
neither
vehicl
drug
treatment
significantli
affect
level
mutat
mrna
transcript
fig
similar
tc
data
figur
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
total
error
rate
viral
significantli
increas
group
treatment
initi
prior
median
error
rate
base
p
post
infect
median
error
rate
base
p
median
error
rate
base
p
error
rate
remain
baselin
group
fig
addit
nucleotid
transit
observ
merscov
genom
vitro
ie
c
u
transit
fig
also
observ
vivo
group
treatment
initi
prior
post
infect
p
fig
importantli
transit
observ
host
mrna
fig
compress
compar
human
sarsand
merscov
lung
titer
peak
mice
concurr
onset
clinic
sign
notabl
damag
lung
epithelium
human
occur
day
onset
symptom
thu
mice
window
within
treat
emerg
cov
infect
prior
peak
replic
compress
eg
much
longer
human
although
specul
sarsand
merscov
vivo
data
provid
herein
suggest
prove
highli
vulner
nhc
treatment
modal
vivo
critic
experi
must
perform
anim
model
becom
avail
data
provid
manuscript
suggest
nhc
quickli
evalu
primat
model
human
diseas
use
immedi
model
merscov
sarscov
pathogenesi
small
molecul
antivir
exert
antivir
effect
multipl
mechan
includ
block
viral
entri
inhibit
viral
encod
enzym
block
viru
particl
format
target
host
factor
requir
replic
vee
exert
antivir
activ
rnadepend
rna
polymeras
lead
error
catastroph
induc
error
rate
replic
surpass
error
threshold
allow
sustain
viru
popul
process
occur
nhc
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
incorpor
rna
synthesi
subsequ
misread
thu
increas
mutat
rate
therefor
nhc
moa
would
appear
less
like
affect
rna
proofread
activ
encod
exonucleas
function
otherwis
limit
misincorper
present
data
use
primer
id
ng
state
art
deep
sequencingbas
approach
quantit
frequenc
ident
mutat
spectra
merscov
genom
drug
treat
primari
human
airway
cell
mice
singl
genom
resolut
cov
posit
sens
rna
virus
replic
neg
sens
rna
intermedi
nhc
incorpor
c
u
occur
polar
rna
use
primer
id
ng
found
increas
nucleotid
transit
g
g
c
u
u
c
consist
report
influenza
vee
infect
ident
condit
remdesivir
alter
mutat
rate
merscov
genom
rna
support
report
mechan
action
chain
termin
viral
rna
synthesi
primari
human
lung
cell
cultur
mice
infect
merscov
nhc
mutat
rate
invers
correl
reduct
infecti
viru
addit
found
posit
correl
increas
mutat
rate
frequenc
nonsynonym
mutat
degre
therapeut
efficaci
mice
explor
potenti
offtarget
effect
host
mrna
may
contribut
drug
toxic
also
examin
impact
nhc
treatment
transcript
highli
merscov
induc
interferon
stimul
gene
present
great
abund
accumul
mutat
observ
model
even
dose
data
also
support
previou
studi
use
rnaseq
demonstr
model
coronaviru
mhv
display
increas
mutat
frequenc
follow
nhc
treatment
vitro
togeth
data
strongli
support
notion
activ
nhc
induc
cytotox
cell
plate
treat
nhc
describ
cell
expos
tenpoint
dilut
seri
creat
vitro
efficaci
studi
dmsotreat
cell
serv
cytotox
control
well
without
cell
serv
cytotox
posit
control
cell
viabil
measur
spectramax
molecular
devic
via
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
vero
cellswel
seed
plate
follow
day
medium
remov
serial
dilut
clarifi
lung
homogen
ad
per
plate
dilut
incub
well
overlay
dmem
fetal
clone
serum
antibioticantimycot
agaros
two
day
plaqu
enumer
gener
plaqueml
valu
lung
hemorrhag
gross
patholog
phenotyp
readili
observ
nake
eye
driven
degre
viru
replic
color
lung
chang
pink
dark
red
larg
left
lobe
place
buffer
formalin
store
follow
vehicl
n
n
n
n
n
number
mice
per
group
merscov
therapeut
studi
follow
vehicl
n
n
n
n
n
describ
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
day
mous
bodi
weight
pulmonari
function
quantit
sarscov
merscov
anim
human
sacrif
tissu
harvest
analyz
describ
addit
merscov
studi
lung
tissu
harvest
store
rnalat
thermo
fisher
thaw
homogen
trizol
reagent
invitrogen
total
rna
isol
use
directzol
rna
miniprep
kit
zymo
research
total
rna
use
primer
id
qrtpcr
proteinac
debri
air
space
none
one
instanc
instanc
e
alveolar
septal
thicken
mock
thick
mock
thick
mock
thick
obtain
lung
injuri
score
per
field
score
ae
put
follow
formula
contain
multipli
assign
vari
level
import
phenotyp
diseas
state
score
x
b
x
c
x
x
e
score
three
field
per
mous
averag
obtain
final
score
rang
includ
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cell
death
factor
express
hae
